SynCore Biotechnology Co Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:SynCore Biotechnology Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013432
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
SynCore Biotechnology Co Ltd (SynCore), a subsidiary of Sinphar Pharmaceutical Co Ltd is a biopharmaceutial company that utilizes and in-licenses technologies to develop new drugs. The company’s pipeline products include SB01, SB02, SB03, SB04 and SB05. Its SB01 drug is a new chemical entity (NCE), which is developed for treating solid tumors, head and neck cancer. SynCore provides SB02 for solid tumors; and SB04 for age-related macular degeneration. The company’s SB05 is a composition of cytostatic drug paclitaxel combined with neutral and positive lipids is being developed for breast cancer. Its marketed product SB03 is an ointment developed for the treatment of external genital warts. The company partners with other pharmaceutical companies, non-profit foundation and biotechnology company. It operates through its offices in I-Lan and Taipei, Taiwan. SynCore is headquartered in Yilan, Taiwan.

SynCore Biotechnology Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
SynCore Biotech to Acquire Rights to EndoTAG-1 from MediGene 10
Partnerships 11
SynCore Biotech Enters into Co-Development Contract with Aju Pharm 11
National Taiwan University Hospital Forms Joint Venture with SynCore Biotech 12
Licensing Agreements 13
MediGene Expands Licensing Agreement With Syncore Biotech For Veregen 13
MediGene Enters Into Licensing Agreement With SynCore Biotechnology For EndoTAG-1 14
MediGene Enters Into Licensing Agreement With Syncore Biotech For Veregen 15
Equity Offering 16
SynCore Biotech to Raise USD8.7 Million in Rights Offering of Shares 16
SynCore Biotech to Raise USD1.1 Million in Public Offering of Shares 17
SynCore Biotech to Raise Funds through Public Offering of Shares 18
SynCore Biotech to Raise Funds through Rights Offering of Shares 19
SynCore Biotechnology Co Ltd – Key Competitors 20
SynCore Biotechnology Co Ltd – Key Employees 21
SynCore Biotechnology Co Ltd – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Joint Venture 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
SynCore Biotechnology Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
SynCore Biotech to Acquire Rights to EndoTAG-1 from MediGene 10
SynCore Biotech Enters into Co-Development Contract with Aju Pharm 11
National Taiwan University Hospital Forms Joint Venture with SynCore Biotech 12
MediGene Expands Licensing Agreement With Syncore Biotech For Veregen 13
MediGene Enters Into Licensing Agreement With SynCore Biotechnology For EndoTAG-1 14
MediGene Enters Into Licensing Agreement With Syncore Biotech For Veregen 15
SynCore Biotech to Raise USD8.7 Million in Rights Offering of Shares 16
SynCore Biotech to Raise USD1.1 Million in Public Offering of Shares 17
SynCore Biotech to Raise Funds through Public Offering of Shares 18
SynCore Biotech to Raise Funds through Rights Offering of Shares 19
SynCore Biotechnology Co Ltd, Key Competitors 20
SynCore Biotechnology Co Ltd, Key Employees 21
SynCore Biotechnology Co Ltd, Other Locations 22
SynCore Biotechnology Co Ltd, Joint Venture 22

★海外企業調査レポート[SynCore Biotechnology Co Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Esperion Therapeutics Inc (ESPR):製薬・医療:M&Aディール及び事業提携情報
    Summary Esperion Therapeutics Inc (Esperion), a subsidiary of Pfizer Inc is a pharmaceutical company that develops and commercializes once-daily, oral and low-density lipoprotein cholesterol lowering therapies. The company develops oral therapies to treat patients with elevated low-density lipoprote …
  • Bio-Modeling Systems SAS-製薬・医療分野:企業M&A・提携分析
    Summary Bio-Modeling Systems SAS (BM Systems) is a mechanism based medicine company which discovers and develops novel diagnostic, therapeutic and prevention solutions. The company owns an operational mechanisms-based medicine platform known as Computer-Assisted Deductive Integration (CADI), which i …
  • Columbus McKinnon Corp (CMCO):企業の財務・戦略的SWOT分析
    Summary Columbus McKinnon Corp (CMCO) is an industrial equipment company that offers cranes and hoists. The company designs, manufactures and markets material handling systems and services, which are used for moving, lifting, positioning and securing materials. Its products include hoists, actuators …
  • Poslovni sistem Mercator, d.d.:企業のM&A・事業提携・投資動向
    Poslovni sistem Mercator, d.d. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Poslovni sistem Mercator, d.d. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Forrester Research, Inc.:企業の戦略・SWOT・財務分析
    Forrester Research, Inc. - Strategy, SWOT and Corporate Finance Report Summary Forrester Research, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • PT Paninvest Tbk:企業の戦略・SWOT・財務情報
    PT Paninvest Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Paninvest Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Tp Icap Plc
    Tp Icap Plc - Strategy, SWOT and Corporate Finance Report Summary Tp Icap Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • The Clorox Company (CLX):企業の財務・戦略的SWOT分析
    The Clorox Company (CLX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Oxford Nanopore Technologies Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Oxford Nanopore Technologies Ltd (Oxford Nanopore), formerly Oxford NanoLabs Ltd., develops disruptive, electronic, and single-molecule sensing system. The company’s products include SmidgION, Flongle, MinION, PromethION and GridION used for the analysis of DNA, RNA, proteins, small molecule …
  • Myriad Genetics Inc (MYGN):医療機器:M&Aディール及び事業提携情報
    Summary Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, which discovers and commercializes molecular diagnostic tests, personalized medicine and services for major diseases. The company’s product portfolio includes molecular diagnostic testing products that analyze genes, t …
  • Peter’s Food Service Ltd:企業の戦略・SWOT・財務情報
    Peter's Food Service Ltd - Strategy, SWOT and Corporate Finance Report Summary Peter's Food Service Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Otsuka Pharmaceutical Co., Ltd.:企業のM&A・事業提携・投資動向
    Otsuka Pharmaceutical Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Otsuka Pharmaceutical Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Maruho Co Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Maruho Co Ltd (Maruho) is a pharmaceutical company that carries out the research, development, production, and distribution of dermatological products. It product portfolio includes a wide range of prescription drugs, medical devices and other skincare products. The company also offers produ …
  • Korea Midland Power Co Ltd-エネルギー分野:企業M&A・提携分析
    Summary Korea Midland Power Co., Ltd. (Komipo), a subsidiary of Korea Electric Power Corporation, is an electric utility which generates electricity; operates power plants; and provides various energy services. The company produces electricity from bituminous coal, anthracite coal, liquefied natural …
  • Verizon Communications Inc (VZ):企業の財務・戦略的SWOT分析
    Verizon Communications Inc (VZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Exact Imaging Inc:医療機器:M&Aディール及び事業提携情報
    Summary Exact Imaging Inc (Exact Imaging) formerly Imagistx Inc, is a provider of high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies for prostate cancer analysis. The company’s ExactVu micro-ultrasound platform operates high resolution conventional and biopsy tra …
  • Companhia Energetica de Minas Gerais SA (CMIG4):電力:M&Aディール及び事業提携情報
    Summary Companhia Energetica de Minas Gerais SA (CEMIG) is an integrated energy utility. Through its subsidiaries and jointly-controlled investees, the company has presence in the electricity vertical. The company produces power from biomass, wind, solar, hydro, fossil, and nuclear sources; and proc …
  • Swissgrid AG:企業の戦略的SWOT分析
    Swissgrid AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • EMC Insurance Group Inc.:企業の戦略・SWOT・財務情報
    EMC Insurance Group Inc. - Strategy, SWOT and Corporate Finance Report Summary EMC Insurance Group Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Stena AB:企業の戦略的SWOT分析
    Stena AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆